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Summary: In the present study the analytical performances of five new liquid applications on the Roche Cobas
Integra were evaluated: urea and high density lipoprotein (HDL) cholesterol in serum and glucose, creatinine and
inorganic phosphorus in urine.
The analytical evaluation consisted of imprecision, linearity and method comparison performed against either the
actual Cobas Integra granulate applications or the corresponding methods on a Hitachi 704, according to the
National Committee for Clinical Laboratory Standards protocols. Over 3700 results were obtained within 3 months.
Average values of within-run and between-day coefficients of variation (CVs) were 1.15% and 1.48%, respectively,
holding to a mean total CV of 2.17%. The linearity was excellent for all the five applications evaluated as the
relative non-linearity was always within 1.53%, thus completely fulfilling the 2.5% upper limit. A strict correlation
was observed by comparing results of 120 samples with either the corresponding granulate applications on Cobas
Integra or the Hitachi reagents. Linear regression analysis of the results yielded correlation coefficients always
above 0.987 and the slopes of the Passing & Bablok regression lines did not deviate by more than 7% from unity.
No drift was observed over 4 hours of operations. In conclusion, the performance of these new Cobas Integra
liquid applications, as demonstrated by the present study, proved them to be highly suitable for routine use in
clinical laboratories.
Introduction
Productivity, quality, rapidity and reduction of the costs
are essential factors in reaching efficiency in modern
clinical laboratories. The first step for the fulfilment of
this objective is the reorganization of the laboratories
and the rationalisation of the work flow, purposes that
can be fairly achieved by the introduction of new, mod-
ern and fast multifunctional analysers able to mate vari-
ous analytical techniques (1). Several clinical chemistry
"consolidated" analysers fulfilling these important
requirements have been presented over the last decade.
The Roche Cobas Integra is a multifunctional random-
and continuous-access clinical chemistry analyser with
a total capacity of 68 tests maintained on board along
with multiple ion-selective electrodes. Eighty-five rea-
gents, contained in cassettes homogeneous in shape and
dimensions, allow the performance of over 111 different
applications in human body fluids. The analyser is pro-
vided by multiple analytical techniques (photometry, tur-
bidimetry, ion selective electrodes and fluorescence po-
larization) that allow simultaneous measurements of dis-
parate common clinical chemistry analytes, enzymes,
proteins, electrolytes, drugs and hormones.
Previous reports have established the analytical perfor-
mances of the instrument equipped with granulate rea-
gents (2—5). The purpose of the present study was the
evaluation of the analytical performances of five new
Cobas Integra liquid reagents designed to replace the
current granulate ones: urea and high-density lipoprotein
(HDL) cholesterol assayed in serum and glucose, inor-
ganic phosphorus and creatinine assayed in urine. Im-
precision, linearity and the method comparison study
were assessed according to the NCCLS protocols
(9-11).
Materials and Methods
Materials
The Cobas Integra was purchased from Roche Diagnostics, a Divi-
sion of F. Hoffmann-La Roche Ltd, Basel, Switzerland. The instru-
ment used for the comparison study was a Hitachi 704 (Boehringer
Mannheim, Mannheim, Germany) (complete technical descriptions
of the instruments are given in I.e. (2, 6)) Original reagents, cali-
brators and controls were used strictly following the instructions
of the manufacturers. Lot numbers were unchanged from the begin-
ning of the evaluation in both analysers.
Imprecision
The imprecision was evaluated according to the NCCLS EP5-T2
protocol (9) and results were expressed in terms of within-run,
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between-day and total imprecision. The study consisted of the eval-
uation of two urine or two serum patient pools (low and high) and
two urine or two serum lyophilized human control materials: Bax-
ter Dade Urine level 1 and 2 for urine (Baxter) or Roche control
N and P for serum (Roche) measurements. The urine and serum
pools were prepared by mixing patients' urine or sera in order to
achieve final concentrations in the lower and in the upper range of
linearity. Aliquots of these pools were stored at -20 °C. Two runs
were performed each day separated by a minimum interval of 4 h
for 20 operating days (6 days a week). After the first run of each
day the samples were tightly closed and stored at 4 °C for further
analysis. The time between the runs was dedicated to daily routine
tests. Within each run the analyte concentration of the samples was
determined in duplicate. Final results were given in terms of CV.
Linearity
The linearity was evaluated according to the NCCLS EP6-P proto-
col (10). A volume of at least 3 ml of patient urine or serum sample
with an analyte concentration close to or slightly exceeding the
claimed upper linear range was used as primary sample and dilu-
tions were performed in saline according to the NCCLS protocol.
A total of twelve concentrations were used, ten obtained by mixing
the starting samples with saline. Starting concentrations and sample
dilutions were assayed in duplicate and average results were used
for the statistical evaluation. The linearity of the assays was eval-
uated using common linear regression and Pearson's correlation
coefficient (r); the relative non-linearity was measured employing
the algorithm described by Emancipator et al. (results below 2.5%
indicate a good linear fit) (12).
Method comparison
The method comparison for the new liquid applications was per-
formed against the current Cobas Integra granulate applications and
with the respective methods available on the Hitachi 704 according
to the NCCLS EP9-T protocol (11). A hundred and twenty ran-
domly selected samples with analyte concentrations evenly distrib-
uted over the assay range of the application were measured in du-
plicate for each application. The experiment was spread over a
period of eight days by testing 15 patient samples each day. Only
fresh urine or serum samples were employed. For serum samples,
blood was drawn daily from volunteers in vacuum tubes containing
no additive. Serum was obtained after 10 min centrifugation at
3000 g and tested with each method within 2 h from venipuncture.
Two controls were analysed daily with the respective method. The
calculation of the parameters was performed according to the Pass-
ing & Bablok non-parametric regression procedure (13); relative
correlation coefficient (r) and standard error of estimated y (Sy>x)
were obtained by linear standard regression.
Results and Discussion
Imprecision
The results of the within-run, between-day and total im-
precision are reported in table 1. Ninety-five percent of
the results were below 2%, either for the within-run or
the between-day imprecision. The mean within-run and
between-day imprecision averaged 1.15% and 1.48%,
respectively, far below the previously proposed accep-
tance criteria (14) and yielding a total mean imprecision
of 2.17%. The acceptance criteria could not be achieved
in only two out of twenty samples. Higher CVs were
observed assaying glucose and phosphorus in urine pool
low (tab. 1). To assess drift of the results, the mean val-
ues obtained early in the morning were compared with
those obtained after the daily routine workload of the
instrument (nearby 4 h). After statistical elaboration of
Tab. 1 Imprescision of serum (HDL-cholesterol and urea) and
urine (inorganic phosphorus, glucose and creatinine) assays eval-
uated on the Cobas Integra according to the NCCLS EP5-T2 proto-
col (9).
Sample Mean
concentration
CV (%)
Within-
run
Between-
run
Total
HDL-cholesterol (mmol/1)
1 0.20
2 0.73
3 1.93
4 1.91
Urea (mmol/1)
1
2
3
4
4.08
5.57
18.91
30.97
Inorganic phosphorus (mmol/1)
1 13.09
2 11.38
3 27.07
4 27.00
Glucose (mmol/1)
1 0.54
2 1.16
3 16.88
4 27.45
Creatinine (mmol/1)
1 4.43
2 6.44
3 18.15
4 15.03
1.47
0.59
0.39
0.26
2.27
1.97
0.82
0.89
1.31
1.21
1.19
0.94
3.40
1.36
0.71
0.63
0.88
1.2
0.66
0.81
2.65
1.71
2.74
1.55
1.02
1.67
1.69
2.46
3.86
0.79
0.87
0.70
1.25
1.13
0.99
0.77
0.62
0.75
0.95
0.19
3.03
2.49
2.95
1.60
3.90
3.20
2.02
2.76
4.63
1.45
1.47
1.40
3.81
1.83
1.26
0.99
1.08
1.42
1.15
0.90
the data by Student's t-test, a significant difference was
observed only for inorganic phosphorus assayed in urine
pool low (p < 0.01). Although no deeper analyses were
conducted, the absence of significant drift in three out
of four samples assayed for inorganic phosphorus and
the concomitant elevated between-run CV (3.86%)
(tab. 1) rule out a defective performance of the instru-
ment, suggesting faulty behaviour of the urine pool.
This finding should not be surprising as the random
acquisition of elevated within-run and between-day
CVs for phosphorus in both urine and serum is fairly
common (6—8).
Linearity
The results of the linearity studies are given in table 2.
All tests evaluated completely fulfilled the major requi-
sites of linearity required for modern clinical chemistry
analysers. The range of linearity met or exceeded the
upper limit claimed by the manufacturer. The evaluation
of the relative non-linearity according to the method of
Emancipator et al. (12) confirmed the excellent results
for each application, ranging from a minimum of 0.19%
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Tab. 2 Linearity of serum (HDL-cholesterol and urea) and urine
(inorganic phosphorus, glucose and creatinine) assays evaluated on
the Cobas Integra according to the NCCLS EP6-P protocol (10).
The linearity of the assays was evaluated by common linear regres-
sion and Pearson 's correlation coefficient; the relative non-linearity
was measured employing the algorithm described by Emancipator
et al. (12).
HDL-
cholesterol
Urea
Inorganic
phosphorus
Glucose
Creatinine
Upper
limit
(mmol/1)
5.18
34.03
53.12
117.54
99.15
Slope
1.00
1.01
0.99
1.00
1.00
Inter-
cept
0.03
0.25
0.08
-0.22
0.16
^y,x
0.02
0.4
0.23
0.47
0.47
Non-
linearity
(%)
0.78
1.53
0.28
0.19
0.64
for glucose to a maximum of 1.53% for urea and hence
constantly lower than the 2.5% limit.
Method comparison
Results of the method comparison between Cobas In-
tegra liquid applications and both Cobas Integra granu-
late applications and Hitachi corresponding methods
are shown in table 3. No significant deviations from
the linearity were observed. The comparison between
Cobas Integra liquid and granulate applications yielded
Passing & Bablok regression slopes not deviating by
more than 6% from unity and correlation coefficients
not beyond 0.998. The results obtained with the Cobas
Integra liquid applications also showed good agree-
ment with the corresponding Hitachi methods. The
regression coefficients were always higher than 0.987,
reaching correlation coefficients of 0.999 or higher for
urea, glucose and phosphorus. The deviation of the
slopes was within a 3% upper limit from unity, the
only exception being phosphorus (7%).
Conclusions
In the present study the analytical performance of five
new liquid applications dedicated to the new Roche Co-
bas Integra chemistry analyser were evaluated. The en-
tire evaluation of the instrument was performed under
routine conditions as Cobas Integra is the principal ana-
lyser in our laboratory. The study for imprecision, linear-
ity and method comparison was carried out according to
the NCCLS protocols (9-11).
The acceptance criteria for the imprecision study could
not be matched only in two out of twenty samples eval-
uated and thus the final results of the three-months eval-
uation reflected good global analytical performances of
the new reagents and were highly comparable to those
previously reported for either the current Cobas Integra
granulate reagents (2—5) or other similar reagents on
other instruments. In summary, the new Cobas Integra
liquid stable applications offer a great advantage over
the current granulate reagents, providing highly compar-
able analytical performances without requiring reconsti-
tution of the granulate reagents and hence ruling out a
potential source of pre-analytical variability.
Tab. 3 Method comparison between analytes measured on the
Cobas Integra by liquid stable reagents (y) and comparison meth-
ods (jc), according to the NCCLS EP9-P protocol (11). Regression
analyses were performed according to the Passing & Bablok non-
parametric regression procedure (13) and relative correlation coef-
ficients (r) were obtained by linear standard regression.
Roche Cobas granulate reagent
HDL-cholesterol
Urea
Inorganic phosphorus
Glucose
Creatinine
Regression
y = l.Oox+0.02
y - l.OOx-0.10
y = 0.98x-0.20
y = l.OOx
y = 0.98x-0.17
Sy, χ
0.01
0.14
0.68
0.02
0.11
r
1.000
1.000
0.999
1.000
0.998
Hitachi reagent
Regression
y = 0.97x-0.12
y - l.Olx-0.44
y = 1.07X-1.24
y = 1.02-0.03
y = 1.03x-0.97
Sy,*
0.03
0.25
0.59
0.07
0.60
r
0.987
1.000
0.999
1.000
0.993
References
1. Lehman CA, Leiken AM. Improving laboratory efficiency
through work flow analysis. In: Ward KM, Lehman CA,
Leiken AM, editors. Clinical laboratory instrumentation and
automation: principles, application and selection. Philadelphia:
Saunders, 1994:444-67.
2. Palmer SM, Kaufman RA, Salamone SJ, Black-Courtney J,
Bette W, Wahl HP, Furrer F. Cobas Integra: clinical laboratory
instrument with continuous and random-access capabilities.
ClinChem 1995; 41:1751-60.
3. Brombacher PJ, Marell GJ, Westerhuis LW. Laboratory work
flow analysis and introduction of a multi-functional analyser.
Eur J Clin Chem Clin Biochem 1996; 34:287-92.
4. Wahl H-P, Augsten H, Manz S, Schmieder M, Van DerMark
DL, Kaufman RA. Performance of absorbance tests on the Co-
bas Integra clinical chemistry analyser. Clin Chem 1993;
39:1222.
5. Bromberg IL, Zielinski N. Precision of the Roche Cobas
Integra for general chemistry tests. Clin Chem 1996;
42:S164.
6. Lentjes EGWM, Harff GA, Backer ET. Evaluation of the
Hitachi 704 automatic analyser. Clin Chem 1987;
33:2089-92.
7. van Straalen JP, Leyte A, Weber JA, Gorgels JP, Sanders
GT. Evaluation of the Hitachi 911 for routine urine analysis
880 Lippi et al.: Evaluation of five new liquid stable applications on the Roche Cobas Integra
and for measurement of various special serum analytes. Eur J
Clin Chem Clin Biochem 1995; 33:315-22.
8. Morosini L, Rossetti M, Berti P, Pallotti G, Fabbri V, Mambelli
MC, et al. Multicentre evaluation of the Bayer DAX system.
Eur J Clin Chem Clin Biochem 1993; 12:875-96.
9. NCCLS Publication EP5-T2. National Committee for Clinical
Laboratory Standards. Evaluation of precision performance of
clinical chemistry devices. Villanova, PA: NCCLS, 1992.
10. NCCLS Publication EP6-P. National Committee for Clinical
Laboratory Standards. Evaluation of the linearity of quantita-
tive analytical methods; proposed guideline. Villanova, PA:
NCCLS, 1986.
11. NCCLS Publication EP9-P. National Committee for Clinical
Laboratory Standards. User comparison of quantitative clinical
laboratory methods using patient samples. Villanova, PA:
NCCLS, 1986.
12. Emancipator KA, Kroll MH. A quantitative measurement of
non-linearity. Clin Chem 1993; 39:752-66.
13. Passing H, Bablok W. A new biometrical procedure for testing
the equality of measurements from two different analytical
methods. Application of linear regression procedure for
method comparison studies in clinical chemistry. Part I. J Clin
Chem Clin Biochem 1983; 21:709-20.
14. Fräser CG, Hyltoft Petersen P, Ricos C, Haeckel R. Proposed
quality specifications for the imprecision and inaccuracy of
analytical systems for clinical chemistry. Eur J Clin Chem Clin
Biochem 1992; 30:311-7.
Received April 15/July 31, 1997
Corresponding author: Prof. Giancesare Guidi, Laboratorio di
Analisi Chimico Cliniche e Microbiologiche, C. O. C. di
Valeggio sul Mincio, 1-37067 Valeggio sul Mincio (VR), Italy
Fax: +39-45-7950188
